Method for treating cancer with an antibody to CD223 protein
Mammals with cancer are treated with an antibody which specifically binds to CD223 protein and inhibits negative T cell regulatory function of CD223. The mammal may be a human. The antibody may be a monoclonal antibody. The amount of the antibody administered may be sufficient to enhance an immune T cell response to the cancer.
1. A method for treating a mammal with a cancer, comprising:
administering to the mammal an antibody which specifically binds to CD223 protein and inhibits negative T cell regulatory function of CD223.
2. The method of claim 1 wherein the mammal is a human cancer patient.
3. The method of claim 1 wherein the antibody is a monoclonal antibody.
4. The method of claim 1 wherein an amount of the antibody is administered which is sufficient to enhance an immune T cell response to the cancer.